U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure -